Evaluation of invitro antifungal activity of selected fungal species tested against opportunistic human pathogen Candida albicans
release_qx6aqzkmtjg6xofuz5c4j3774e
by
Aakriti Shukla,
Apoorva Pathak
2020 Issue 01, p01-08
Abstract
Candida albicans is currently the fourth-leading cause of hospital-acquired bloodstream infections, reaching a mortality rate up to 35–40% for systemic or disseminated infections. Systemic mycoses can occur in patients with severely impaired immune systems (AIDS), with organ or bone marrow transplants, cancer patients undergoing chemotherapy and patients in ICU (neonates and elderly). It is therefore, obvious that there is substantial need for fast effective antifungal antibiotics to combat fungal infections. The present investigation has been proposed to screen effective fungal metabolites for the control of Candida albicans by evaluating the potential of fungal bioactive compounds, its purification and characterization.
In application/xml+jats
format
Archived Files and Locations
application/pdf
1.7 MB
file_q4anebylefbpbbsxj7lenmyvou
|
ijpbr.in (web) web.archive.org (webarchive) |
article-journal
Stage
published
Date 2020-03-27
access all versions, variants, and formats of this works (eg, pre-prints)
Crossref Metadata (via API)
Worldcat
SHERPA/RoMEO (journal policies)
wikidata.org
CORE.ac.uk
Semantic Scholar
Google Scholar